Top

Advances in Therapy

Published in:

Open Access 01-06-2016 | Review

Management of Pemphigus Vulgaris

Authors: Mimansa Cholera, Nita Chainani-Wu

Published in: Advances in Therapy | Issue 6/2016

Abstract

Introduction

Pemphigus vulgaris (PV) is a chronic, autoimmune, vesiculobullous disease. As a result of the relative rarity of PV, published randomized controlled trials (RCTs) are limited, which makes it difficult to evaluate the efficacy of different treatment regimens in this disease. This also precludes conduct of a meta-analysis.

Methods

English-language publications describing treatment outcomes of patients with PV were identified by searches of electronic databases through May 2015, and additionally by review of the bibliography of these publications. A total of 89 papers, which included 21 case reports, 47 case series, 8 RCTs, and 13 observational studies, were identified. The findings from these publications, including information on disease course and prognosis, medications used, treatment responses, and side effects, are summarized in the tables and text of this review.

Results

Prior to availability of corticosteroid therapy, PV had a high fatality rate. Early publications from the 1970s reported high-dose, prolonged corticosteroid use and significant associated side effects. Later reports described use of corticosteroids along with steroid-sparing adjuvants, which allows a reduction in the total dose of corticosteroids and a reduction in observed mortality and morbidity. For the majority of patients in these reports, a long-term course on medications lasting about 5–10 years was observed; however, subgroups of patients requiring shorter courses or needing longer-term therapy have also been described. Early diagnosis of PV and early initiation of treatment were prognostic factors. In recent publications, commonly used initial regimens include corticosteroids in combination with mycophenolate or azathioprine; whereas, for patients with inadequate response to these regimens, adjuvants such as intravenous immunoglobulin (IVIg) or rituximab are used.

Conclusion

The review findings emphasize the importance of early diagnosis, early initiation of treatment, and use of steroid-sparing adjuvants to allow a reduced total dose and duration on corticosteroids. Also highlighted is the need for more RCTs.

Chaidemenos G, Apalla Z, Koussidou T, Papagarifallou I, Ioannides D. High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study. J Eur Acad Dermatol Venereol. 2011;25(2):206–10. doi:10.1111/j.1468-3083.2010.03753.x [Epub 2010 Jun 21].PubMedCrossRef

Burgan SZ, Sawair FA, Napier SS. Case report: oral pemphigus vulgaris with multiple oral polyps in a young patient. Int Dent J. 2003;53(1):37–40.PubMedCrossRef

Iamaroon A, Boonyawong P, Klanrit P, Prasongtunskul S, Thongprasom K. Characterization of oral pemphigus vulgaris in Thai patients. J Oral Sci. 2006;48(1):43–6.PubMedCrossRef

Santoro FA, Stoopler ET, Werth VP. Pemphigus. Dent Clin North Am. 2013;57(4):597–610. doi:10.1016/j.cden.2013.06.002 (Epub 2013 Aug 12. Review).PubMedCrossRef

Ariyawardana A, Tilakaratne WM, Dissanayake M, et al. Oral pemphigus vulgaris in children and adolescents: a review of the literature and a case report. Int J Paediatr Dent. 2005;15(4):287–93.PubMedCrossRef

Deyhimi P, Tavakoli P. Study of apoptosis in oral pemphigus vulgaris using immunohistochemical marker Bax and TUNEL technique. J Oral Pathol Med. 2013;42(5):409–14. doi:10.1111/jop.12022 [Epub 2012 Nov 27].PubMedCrossRef

Endo H, Rees TD, Matsue M, Kuyama K, Nakadai M, Yamamoto H. Early detection and successful management of oral pemphigus vulgaris: a case report. J Periodontol. 2005;76(1):154–60.PubMedCrossRef

Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;30(1):78–83. doi:10.1016/j.clindermatol.2011.03.013.PubMedCrossRef

Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996;132(2):203–12.PubMedCrossRef

10.

Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043–6. doi:10.1016/j.jaad.2008.01.012 [Epub 2008 Mar 14].PubMedPubMedCentralCrossRef

11.

Becker KL, editor. Principles and practice of endocrinology and metabolism, 3rd ed. 2001. Philadelphia: Lippincott Williams & Wilkins

12.

Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113(9):1236–41.PubMedCrossRef

13.

Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol. 1984;120(1):44–7.PubMedCrossRef

14.

Lozada F, Silverman S, Cram D. Pemphigus vulgaris. A study of six cases treated with levamisole and prednisone. Oral Surg Oral Med Oral Pathol. 1982;54(2):161–5.PubMedCrossRef

15.

David M, Zaidenbaum M, Sandbank M. Juvenile pemphigus vulgaris: a 4- to 19-year follow-up of 4 patients. Dermatologica. 1988;177(3):165–9.PubMedCrossRef

16.

Lamey PJ, Rees TD, Binnie WH, Wright JM, Rankin KV, Simpson NB. Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. Oral Surg Oral Med Oral Pathol. 1992;74(1):54–7.PubMedCrossRef

17.

Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol. 1990;29(5):371–4.PubMedCrossRef

18.

Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus. Dermatology. 2002;204(3):228–31.PubMedCrossRef

19.

Mentink LF, Mackenzie MW, Tóth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol. 2006;142(5):570–6 (Erratum in: Arch Dermatol. 2006 Aug;142(8):1014. Dosage error in article text).PubMedCrossRef

20.

Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995;17(6):681–4.PubMedCrossRef

21.

Powell AM, Albert S, Al Fares S, et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149(1):138–45.PubMedCrossRef

22.

Scheinfeld NS. Intravenous immunoglobulin. Drugs Dis Proced. Medscape Reference; 2011. Web 14 Mar 2016.

23.

Ruocco E, Wolf R, Ruocco V, Brunetti G, Romano F, Lo Schiavo A. Pemphigus: associations and management guidelines: facts and controversies. Clin Dermatol. 2013;31(4):382–90. doi:10.1016/j.clindermatol.2013.01.005.PubMedCrossRef

24.

Tsuruta D, Ishii N, Hashimoto T. Diagnosis and treatment of pemphigus. Immunotherapy. 2012;4(7):735–45.PubMedCrossRef

25.

Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica. 2003;88(7):ELT24.PubMed

26.

Fleischli ME, Valek RH, Pandya AG. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol. 1999;135(1):57–61.PubMedCrossRef

27.

Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28(6):998–1000.PubMedCrossRef

28.

Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;1:CD006263. doi:10.1002/14651858.CD006263.pub2.PubMed

29.

Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42(3):422–7.PubMedCrossRef

30.

Dagistan S, Goregen M, Miloglu O, Cakur B. Oral pemphigus vulgaris: a case report with review of the literature. J Oral Sci. 2008;50(3):359–62.PubMedCrossRef

31.

Ben Lagha N, Poulesquen V, Roujeau JC, Alantar A, Maman L. Pemphigus vulgaris: a case-based update. J Can Dent Assoc. 2005;71(9):667–72.PubMed

32.

Robinson NA, Yeo JF, Lee YS, Aw DC. Oral pemphigus vulgaris: a case report and literature update. Ann Acad Med Singapore. 2004;33(4 Suppl):63–8.PubMed

33.

Camacho-Alonso F, López-Jornet P, Bermejo-Fenoll A. Pemphigus vulgaris. A presentation of 14 cases and review of the literature. Med Oral Patol Oral Cir Bucal. 2005;10(4):282–8.PubMed

34.

Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153(3):620–5.PubMedCrossRef

35.

Heelan K, Al-Mohammedi F, Smith MJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150(7):703–8.PubMedCrossRef

36.

Baican A, Chiorean R, Leucuta DC, et al. Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study. Orphanet J Rare Dis. 2015;22(10):48. doi:10.1186/s13023-015-0263-4.CrossRef

37.

Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67(4):617–22. doi:10.1016/j.jaad.2011.11.007 [Epub 2012 Jan 13].PubMedCrossRef

38.

Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44(6):470–6.PubMedCrossRef

39.

Yazganoğlu KD, Baykal C, Küçükoğlu R. Childhood pemphigus vulgaris: five cases in 16 years. J Dermatol. 2006;33(12):846–9.PubMedCrossRef

40.

Ryan JG. Pemphigus. A 20-year survey of experience with 70 cases. Arch Dermatol. 1971;104(1):14–20.PubMedCrossRef

41.

Berger BW, Maier HS, Kantor I, Wexler DE. Pemphigus vulgaris in a 3½-year old boy. Arch Dermatol. 1973;107(3):433–4. doi:10.1001/archderm.1973.01620180083027.PubMedCrossRef

42.

Rosenberg FR, Sanders S, Nelson CT. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol. 1976;112(7):962–70.PubMedCrossRef

43.

Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol. 1987;16(3 Pt 1):527–33.PubMedCrossRef

44.

Seidenbaum M, David M, Sandbank M. The course and prognosis of pemphigus. A review of 115 patients. Int J Dermatol. 1988;27(8):580–4.PubMedCrossRef

45.

Laskaris G, Stoufi E. Oral pemphigus vulgaris in a 6-year-old girl. Oral Surg Oral Med Oral Pathol. 1990;69(5):609–13 (Review).PubMedCrossRef

46.

Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1996;132(12):1435–9.PubMedCrossRef

47.

Robinson JC, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris: a review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(4):349–55.PubMedCrossRef

48.

Mignogna MD, Lo Muzio L, Mignogna RE, Carbone R, Ruoppo E, Bucci E. Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases. J Oral Pathol Med. 2000;29(4):145–52.PubMedCrossRef

49.

Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol. 1999;140(1):84–9.PubMedCrossRef

50.

Ljubojević S, Lipozencić J, Brenner S, Budimcić D. Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol. 2002;16(6):599–603.PubMedCrossRef

51.

Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol. 2002;16(4):353–6.PubMedCrossRef

52.

Chaidemenos GCh, Mourellou O, Koussidou T, Tsatsou F. An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study. J Eur Acad Dermatol Venereol. 2007;21(10):1386–91.PubMedCrossRef

53.

Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622–8 Epub 2007 Jun 21.PubMedCrossRef

54.

Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169(4):916–21. doi:10.1111/bjd.12474.PubMedCrossRef

55.

Mignogna MD, Fortuna G, Leuci S, Adamo D, Dell’Aversana Orabona G, Ruoppo E. Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2010;24(10):1157–65. doi:10.1111/j.1468-3083.2010.03610.x.PubMedCrossRef

56.

Mourellou O, Chaidemenos GC, Koussidou T, Kapetis E. The treatment of pemphigus vulgaris. Experience with 48 patients seen over an 11-year period. Br J Dermatol. 1995;133(1):83–7.PubMedCrossRef

57.

Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27(10):1285–92. doi:10.1111/j.1468-3083.2012.04717.x [Epub 2012 Oct 15].PubMed

58.

Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;135(1):54–6.PubMedCrossRef

59.

Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6 Pt 1):957–60.PubMedCrossRef

60.

Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139(6):739–42.PubMedCrossRef

61.

Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142(11):1447–54.PubMedCrossRef

62.

Strowd LC, Taylor SL, Jorizzo JL, Namazi MR. Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. J Am Acad Dermatol. 2011;64(3):490–4. doi:10.1016/j.jaad.2010.02.052 [Epub 2010 Jul 14].PubMedCrossRef

63.

Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130(8):2041–8. doi:10.1038/jid.2010.91 [Epub 2010 Apr 22].PubMedCrossRef

64.

Bongiorno MR, Pistone G, Doukaki S, Aricò M. Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus. Int J Dermatol. 2010;49(6):693–9. doi:10.1111/j.1365-4632.2009.04291.x.PubMedCrossRef

65.

Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol. 2012;26(7):855–60. doi:10.1111/j.1468-3083.2011.04170.x [Epub 2011 Jul 14].PubMedCrossRef

66.

Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002;47(3):358–63.PubMedCrossRef

67.

Amagai M, Ikeda S, Pemphigus Study Group, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595–603. doi:10.1016/j.jaad.2008.09.052.PubMedCrossRef

68.

Rakocević-Stojanović V, Rakocević I, Perić S, Lavrnić D. Intravenous immunoglobulin therapy in two patients with myasthenia gravis and pemphigus vulgaris. Acta Myol. 2009;28(3):101–2.PubMedPubMedCentral

69.

Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol. 1969;100(1):70–8.PubMedCrossRef

70.

Jablonska S, Chorzelski T, Blaszczyk M. Immunosuppressants in the treatment of pemphigus. Br J Dermatol. 1970;83(2):315–23 (Review).PubMedCrossRef

71.

Piamphongsant T, Sivayathorn A. Pemphigus: combined treatment with methotrexate and prednisone. J Med Assoc Thai. 1975;58(3):171–6.PubMed

72.

73.

Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol. 1972;106(4):491–7.PubMedCrossRef

74.

Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol. 1988;68(5):413–21.PubMed

75.

Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999;135(10):1275–6.PubMedCrossRef

76.

Baum S, Greenberger S, Samuelov L, et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22(1):83–7. doi:10.1684/ejd.2011.1611.PubMed

77.

Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47(5):785–8.PubMedCrossRef

78.

Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol. 2003;28(4):366–8.PubMedCrossRef

79.

España A, Fernández-Galar M, Lloret P, Sánchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50(6):974–6.PubMedCrossRef

80.

Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51(5):817–9.PubMedCrossRef

81.

Wenzel J, Bauer R, Bieber T, Tüting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol. 2005;85(2):185–6.PubMed

82.

Dupuy A, Viguier M, Bédane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140(1):91–6.PubMedCrossRef

83.

Kong HH, Prose NS, Ware RE, Hall RP 3rd. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol. 2005;22(5):461–4.PubMedCrossRef

84.

Schmidt E, Herzog S, Bröcker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol. 2005;153(2):449–51.PubMedCrossRef

85.

Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–6.PubMedCrossRef

86.

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–9.PubMedCrossRef

87.

Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol. 2007;156(5):990–6 [Epub 2007 Mar 13].PubMedCrossRef

88.

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology. 2007;214(4):310–8.PubMedCrossRef

89.

Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatol Treat. 2007;18(3):178–83.CrossRef

90.

Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 2007;143(8):1033–8 (Review).PubMedCrossRef

91.

Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545–52.PubMedCrossRef

92.

Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol. 2008;158(2):382–8 [Epub 2007 Dec 6].PubMedCrossRef

93.

Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850–8. doi:10.1038/jid.2008.172 [Epub 2008 Jun 19].PubMedCrossRef

94.

Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008;47(3):292–4. doi:10.1111/j.1365-4632.2008.03423.x.PubMedCrossRef

95.

Pfütze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology. 2009;218(3):237–45. doi:10.1159/000187431 Epub 2008 Dec 16.PubMedCrossRef

96.

Fuertes I, Guilabert A, Mascaró JM Jr, Iranzo P. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature. Dermatology. 2010;221(1):13–6. doi:10.1159/000287254 (Epub 2010 Apr 9. Review).PubMedCrossRef

97.

Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166(1):154–60. doi:10.1111/j.1365-2133.2011.10585.x [Epub 2011 Oct 17].PubMedCrossRef

98.

Craythorne E, du Viver A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011;40(8):616–20. doi:10.1111/j.1600-0714.2011.01017.x [Epub 2011 Mar 9].PubMedCrossRef

99.

Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552–8. doi:10.1016/j.jaad.2010.07.032.PubMedCrossRef

100.

Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165(3):646–51. doi:10.1111/j.1365-2133.2011.10411.x.PubMedCrossRef

101.

Reguiai Z, Tabary T, Maizières M, Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012;67(4):623–9. doi:10.1016/j.jaad.2011.12.019 [Epub 2012 Jan 20].PubMedCrossRef

102.

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405–12. doi:10.1111/j.1365-2133.2011.10663.x [Epub 2012 Jan 9].PubMedCrossRef

103.

Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Br J Dermatol. 2012;166(3):511–7. doi:10.1111/j.1365-2133.2011.10658.x [Epub 2012 Jan 19].PubMedCrossRef

104.

Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68(3):404–11. doi:10.1016/j.jaad.2012.08.010 [Epub 2012 Oct 6].PubMedCrossRef

105.

Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031–6. doi:10.1001/archdermatol.2012.1522.PubMedPubMedCentralCrossRef

106.

Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges. 2012;10(10):727–32. doi:10.1111/j.1610-0387.2012.07931.x [Epub 2012 May 11].PubMed

107.

Balighi K, Daneshpazhooh M, Khezri S, Mahdavi-nia M, Hajiseyed-javadi M, Chams-Davatchi C. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52(7):862–7. doi:10.1111/j.1365-4632.2012.5847.x (Erratum in: Int J Dermatol. 2013 Oct;52(10):1292. Kamran, Balighi [corrected to Balighi, Kamran]; Maryam, Daneshpazhooh [corrected to Daneshpazhooh, Maryam]; Somayeh, Khezri [corrected to Khezri, Somayeh]; Mostafa, Mahdavi-nia [corrected to Mahdavi-nia, Mostafa]; Mahsa, Hajiseyed-javadi [corrected to Hajiseyed-javadi, Mahsa]; Cheyda, Chams-Davatchi [corrected to Chams-Davatchi, Cheyda]).PubMedCrossRef

108.

Kanwar AJ, Tsuruta D, Vinay K, et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013;27(1):e17–23. doi:10.1111/j.1468-3083.2011.04391.x [Epub 2011 Dec 17].PubMedCrossRef

109.

Kolesnik M, Becker E, Reinhold D, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol. 2014;28(6):771–80. doi:10.1111/jdv.12175 [Epub 2013 May 8].PubMedCrossRef

110.

Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):1341–9. doi:10.1111/bjd.12972.PubMedCrossRef

111.

Ojaimi S, O’Connor K, Lin MW, Schifter M, Fulcher DA. Treatment outcomes in cohort of patients with mucosal-predominant pemphigus vulgaris. Intern Med J. 2015;45(3):284–92. doi:10.1111/imj.12674.PubMedCrossRef

Title: Management of Pemphigus Vulgaris
Authors: Mimansa Cholera
Nita Chainani-Wu
Publication date: 01-06-2016
Publisher: Springer Healthcare
Published in: Advances in Therapy / Issue 6/2016
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-016-0343-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Management of Pemphigus Vulgaris

Abstract

Introduction

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2016

Weight Loss: A Patient and Physician’s Perspective

Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT

Erratum to: Quality of Life in Glaucoma: A Review of the Literature

Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer

Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee

Quality of Life in Glaucoma: A Review of the Literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page